PLATT DAVID 4
4 · BIOXYTRAN, INC · Filed Aug 20, 2024
Insider Transaction Report
Form 4
BIOXYTRAN, INCBIXT
PLATT DAVID
DirectorCEO10% Owner
Transactions
- Other
preferred
2024-08-19$0.81/sh+4,335,188$3,494,162→ 4,335,188 total(indirect: by NDPD Pharma) - Other
common
2024-08-19$0.16/sh−21,675,939$3,511,502→ 0 total(indirect: by NDPD Pharma) - Other
preferred
2024-08-19$0.46/sh+776,817$354,229→ 14,085,410 total(indirect: by NDPD Pharma) - Other
common
2024-08-19$0.00/sh−411,300$411→ 0 total(indirect: by Naomi Platt) - Other
preferred
2024-08-19$0.01/sh+8,605,455$43,027→ 8,605,455 total - Purchase
common
2024-08-15$0.12/sh+1,592,921$197,522→ 21,675,939 total(indirect: by NDPD Pharma) - Conversion
preferred
2024-08-19$0.02/sh+8,973,405$161,521→ 13,308,593 total(indirect: by NDPD Pharma) - Other
preferred
2024-08-19$0.01/sh+82,260$411→ 82,260 total(indirect: by Naomi Platt) - Other
common
2024-08-19$0.00/sh−43,027,274$43,027→ 0 total
Footnotes (4)
- [F1]Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing.
- [F2]A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock.
- [F3]The shares were acquired through conversion of debt, issued under Rule 3(a)(9).
- [F4]Total holdings by Naomi Platt, spouse of David Platt.